Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for female stress urinary incontinence
NCT04984317Phase 1Suspended
- Sponsor
- Northwell Health
- Start
- Feb 2022
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of botulinum toxin type A in stress urinary incontinence (SUI), sponsored by Northwell Health. Primary endpoint: Change in the amount of urinary leakage at 6 months. Started Feb 2022; status: suspended.
02
Drugs
botulinum toxin type A
03
Conditions
stress urinary incontinence (SUI)
Beyond the preview
Go deeper on NCT04984317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984317.